Q&AInnovations in Clinical Trial DesignErica Tennenhouse, PhD | September 4, 2020 Matthew M. Laughon, MD, MPH is a professor at the University of North Carolina (UNC) at Chapel Hill in thedepartment of pediatrics.
RegulatoryWhen is it Ethical to Stop a Clinical Trial?Nicholas G. Evans, PhD | September 4, 2020 The benefits of ending a trial early must be weighed carefully against the risks
NewsScientists Use Blood Test to Predict Who Is Likely to Develop Psychotic DisordersRCSI University of Medicine and Health Sciences | September 1, 2020 Certain proteins in blood samples can predict whether a person at risk of psychosis is likely to develop a psychotic disorder
RegulatoryNew Reporting Requirements for Hospital Outreach LabsKimberly Scott | March 31, 2019 Hospital outreach labs are now challenged to collect and report private payer pricing, but there may be an upside
BusinessThe Hidden Value in the Clinical LabKathleen Swanson, MS, RPh | January 1, 2019 Laboratory data will play a starring role in healthcare's transition from sick care to well care
InsightClinical Microbiology Meets Total Laboratory AutomationBlake W. Buchan, PhD, D(ABMM) | December 1, 2018 In the past, specimen diversity and analytic complexity have prevented microbiology labs from adopting an automated approach
Applications & ProductsSponsoredBetter Connectivity=Greater ProductivityMilliporeSigma | December 1, 2018 How a connected water purification system can address the critical needs of the clinical laboratory
RegulatoryBiobanks as Mediators Between Researchers and DonorsMichelle Dotzert, PhD | November 21, 2018 Better communication about privacy and confidentiality can help encourage potential biobank donors
NewsA 15-Minute Scan Could Help Diagnose Brain Damage in NewbornsImperial College London | November 15, 2018 In a study of more than 200 babies, magnetic resonance spectroscopy predicted damage with 98 percent accuracy
NewsPulmonary Tuberculosis Can Be Cured with Shorter TreatmentUniversity of California - San Francisco | November 6, 2018 The new study re-analyzed data from three pivotal TB trials that had failed to show the efficacy of four-month treatments over the standard six-month duration